复方丹参滴丸(T89)完成美国FDA三期临床试验

2016-12-24 赵敬菡 人民网

导语:复方丹参滴丸首个完成美国FDA三期临床试验,具有里程碑意义。12月23日下午,上海证券交易所官方网站发布《天士力制药集团股份有限公司关于复方丹参滴丸美国 FDA 国际多中心Ⅲ期临床试验结果的公告》,公告中称,天士力制药集团股份有限公司在中国已上市的独家产品复方丹参滴丸为申报美国 FDA (美国食品药品监督管理局)在美国新药上市批准进行的全球多中心随机双盲大样本Ⅲ期临床试验,经过一系列数据管理

小编提示:

检索clinicaltrials,发现T89(复方丹参滴丸)尚未完成试验(相关链接)。因为在今年夏天更新信息时,仍然显示未招募患者,如今短短半年能完成试验,除非神速。不过,夏天更新信息时,确实提到试验结束时间为2016年7月。具体事实情况,只有厂家最为清楚。如果试验确实完成,建议厂家立即更新一下Clinicaltrials上信息,不然太难看了。


但是,不管怎么说遗憾的是2012年完成phase 2研究时,竟然没有发表高水平的研究论文?或是没有在Clinicaltrials网站上标明。

下面是新闻报道:

12月23日下午,上海证券交易所官方网站发布《天士力制药集团股份有限公司关于复方丹参滴丸美国 FDA 国际多中心Ⅲ期临床试验结果的公告》,公告中称,天士力制药集团股份有限公司在中国已上市的独家产品复方丹参滴丸为申报美国 FDA (美国食品药品监督管理局)在美国新药上市批准进行的全球多中心随机双盲大样本Ⅲ期临床试验,经过一系列数据管理和统计分析工作,形成了《临床试验顶层分析总结报告》。复方丹参滴丸治疗慢性稳定性心绞痛的美国 FDAⅡ期临床试验的安全性、有效性结果得到进一步验证。



复方丹参滴丸首个完成美国FDA三期临床试验,具有里程碑意义

FDA(美国食品药物管理局)是国际医疗药品审核权威机构,其严格的检测和评估是目前世界上最先进、最严格的新药审评机构。在美国等近百个国家,只有通过了FDA认可的药品和技术才能进行商业化临床应用。FDA第一期试验的重点是药物的安全性,第二期试验的重点是药物的有效性。如二期试验证明药物的有效性,就进入三期试验。该阶段研究主要是收集大样本量的关于安全性和有效性的研究数据,对不同人群、不同剂量及该药物与其它药物的配伍进行临床研究。完成三期临床试验后,即可申报新药药物批准上市。

天士力复方丹参滴丸于1993年获得国家新药证书和生产批件,目前作为国家行政保护品种、国家基本药物、国家医疗保险药物和中医急救必备药物,已成为治疗冠心病心绞痛临床一线基本用药得到广泛使用,深受广大医生与患者的好评。从1998年开始,经过20年的面对美国FDA申报所进行的研究工作,工艺技术与质量标准已达到美国先进质量标准,经受住了世界最严格临床试验的评价,顺利完成美国FDA三期临床试验,并取得良好的临床试验结果,成为全球首例完成美国FDA三期试验的复方中药制剂,实现了中药历史性的跨越与突破,首次向世人证实复方中药也可按国际标准进行临床评价,为中药走向世界带来光辉前景。

天士力集团负责人介绍,这一成果的取得,依赖于科技与标准创新的结果。作为国家十五、十一五、十二五、十三五、国家863、973、国家重大新药创制科技重大专项的研究项目,对复方丹参滴丸药材种植质量规范、药物有效成分、制剂工艺、质量标准、药理药效、临床疗效和安全性等方面进行了深入系统的研究。复方丹参滴丸美国FDA三期临床试验的成功,完善和发展了现代中药的国际化先进评价体系,将对中药国际化发展产生巨大影响。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
    2017-09-14 lijianyu118

    天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
    2017-01-03 1e10c84am36(暂无匿称)

    文章真好,已拜读

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
    2016-12-28 圣艮山

    这个的确厉害!!!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
    2016-12-26 1df01bccm39(暂无匿称)

    中医拯救师姐

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2071075, encodeId=6dd820e10755b, content=<a href='/topic/show?id=f96e42642ea' target=_blank style='color:#2F92EE;'>#复方丹参滴丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42642, encryptionId=f96e42642ea, topicName=复方丹参滴丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Apr 07 19:20:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243881, encodeId=6c5a243881a8, content=天士力的老总在药学大会称.复方丹参滴丸将成为第一个FDA批准的中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/a151a58fc4d13574f3d5c622c4a0ced3.jpg, createdBy=f4652136579, createdName=lijianyu118, createdTime=Thu Sep 14 10:34:40 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Apr 20 21:20:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030028, encodeId=36e12030028c0, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Sun Oct 15 03:20:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167656, encodeId=0c4516e65650, content=文章真好,已拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Jan 03 10:11:02 CST 2017, time=2017-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995384, encodeId=5eb8199538499, content=<a href='/topic/show?id=2e0642641f7' target=_blank style='color:#2F92EE;'>#复方丹参#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42641, encryptionId=2e0642641f7, topicName=复方丹参)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Oct 10 20:20:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166244, encodeId=6d3b16624483, content=这个的确厉害!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 28 08:38:48 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551382, encodeId=9c241551382aa, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Mon Dec 26 13:20:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165713, encodeId=d97b165e1383, content=中医拯救师姐, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Dec 26 07:04:13 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165561, encodeId=11cd165561d6, content=学习下,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sun Dec 25 11:30:22 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
    2016-12-25 1771ae4158m

    学习下,好

    0